
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BOSTON , May 02, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on April 30, 2025, the company granted equity awards to seven new employees, …